Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 and Sitagliptin Interaction Study in Healthy Males
NCT02172196Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2009
- Primary completion
- Jul 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve at steady state. Started May 2009; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02172196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172196.